Skip to content
10-Q

Quarterly Report

bluebird bio, Inc.

0001293971-24-000040

← back to feed
Filed
Sep 13, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Sep 11, 2024 193.91M sh
Short Term Debt Q1 2024 · Mar 31, 2024 $69M
Short Term Debt Q1 2024 · Dec 31, 2023 $0
Current Liabilities Q1 2024 · Mar 31, 2024 $293.57M
Current Liabilities Q1 2024 · Dec 31, 2023 $200.11M
Total Liabilities Q1 2024 · Mar 31, 2024 $500.44M
Total Liabilities Q1 2024 · Dec 31, 2023 $424.62M
Current Assets Q1 2024 · Mar 31, 2024 $271.6M
Current Assets Q1 2024 · Dec 31, 2023 $281.69M
Total Assets Q1 2024 · Mar 31, 2024 $631.48M
Total Assets Q1 2024 · Dec 31, 2023 $619.16M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $221.76M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $239.05M
Shares Diluted Q1 2024 · Mar 31, 2023 103.3M sh
Capex Q1 2024 · Mar 31, 2023 $232K
Operating Cash Flow restated Q1 2024 · Mar 31, 2023 −$71.36M
Stockholders Equity restated Q1 2024 · Mar 31, 2023 $290.42M
Stockholders Equity restated Q1 2024 · Dec 31, 2022 $134.33M
Eps Diluted restated Q1 2024 · Mar 31, 2023 $0.18
Eps Basic restated Q1 2024 · Mar 31, 2023 $0.18
Sga Expense restated Q1 2024 · Mar 31, 2023 $37.47M
Rd Expense restated Q1 2024 · Mar 31, 2023 $41.59M
Net Income restated Q1 2024 · Mar 31, 2023 $18.93M
Operating Income restated Q1 2024 · Mar 31, 2023 $10.75M
Gross Profit restated Q1 2024 · Mar 31, 2023 −$3.13M
Cost Of Revenue restated Q1 2024 · Mar 31, 2023 $5.51M
Revenue Q1 2024 · Mar 31, 2023 $2.3M